Funding for this research was provided by:
Received: 27 June 2018
Accepted: 4 January 2019
First Online: 24 January 2019
Change Date: 28 May 2019
Change Type: Correction
Change Details: The publisher has retracted this article  because the incorrect version of the article was published in error.
Ethics approval and consent to participate
: The study protocols and all documentation were approved by the Institutional Review Boards or Independent Ethics Committees at each investigational site. All patients provided written informed consent.
: Not applicable.
: David Cella has served on the board of directors for Cancer Wellness Center, and PROMIS Health Organization, has received consultancy fees of <$10,000 from AbbVie, Alexion Pharmaceuticals, Astellas Pharma, Bayer AG, Bristol-Myers Squibb, Celgene Corporation, Clovis Oncology Inc., Evidera, Exelixis Inc., FibroGen Inc., Helsinn Therapeutics (U.S.) Inc., Horizon Pharma Inc., ImmunoGen Inc., Janssen Pharmaceuticals Inc., Merck/Schering-Plough Pharmaceuticals, National Academy of Sciences, Novartis Pharma K.K. (Japan), PatientsLikeMe, Pfizer Inc., Pled Pharma, Puma Biotechnology Inc., Regeneron Pharmaceuticals Inc., and Shire PLC, and has ownership or investment interests in FACITtrans LLC (FACIT.org), and Functional Assessment of Chronic Illness Therapy (FACIT.org). Hilary Wilson, Huda Shalhoub and Dennis A. Revicki are employees of Evidera Inc. Joseph C. Cappelleri, Andrew G. Bushmakin, Elizabeth Kudlacz and Ming-Ann Hsu are employees of Pfizer Inc. and own stock in Pfizer Inc.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.